Professor, Internal Medicine, University of Kentucky College of Medicine
Gastroenterology
Dr. Paul Angulo, MD
|
|
Give Review
Paul Angulo is an expert in the field of Gastroenterology. He received awards:"CMS Meaningful Use Stage 1 Certification", "Fellow (AGAF)" and "Fellow (FACG)". Paul Angulo, MD is a published physician. He published 98 publications, including: 'Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.' Dr. Paul Angulo is registered with Medicare and accepts Medicare payments.
Publications
- The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease.
- Editorial: noninvasive prediction of hepatic steatosis.
- Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver Disease.
- Hepatic steatosis and steatoHepatitis: Are they really two distinct entities?
- Right Upper-Quadrant Pain in a Patient with Drug Abuse, Secondary Syphilis and Occult Hepatitis B Virus.
- PKI-587 and sorafenib alone and in combination on inhibition of liver Cancer stem cell proliferation.
- Strengthing the bones in primary Biliary cirrhosis.
- Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
- Risk factors for venous thromboembolism in patients with chronic liver Disease.
- Can nash be diagnosed, graded, and staged noninvasively?
- The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver Disease.
- Cryoglobulins in nonalcoholic Fatty-liver Disease: what is the association?
- Incomplete response to ursodeoxycholic acid in primary Biliary cirrhosis: is a double dosage worthwhile?
- Nutritional and metabolic considerations in the etiology of nonalcoholic steatoHepatitis.
- Development of autoimmune hepatitis in the setting of long-standing primary Biliary cirrhosis.
- Bone disease in primary Biliary cirrhosis: independent indicators and rate of progression.
- Fat-soluble vitamin levels in patients with primary Biliary cirrhosis.
- Betaine, a promising new agent for patients with nonalcoholic steatoHepatitis: results of a pilot study.
- Severe cholestatic Hepatitis from troglitazone in a patient with nonalcoholic steatoHepatitis and diabetes mellitus.
- High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
- Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience.
- Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.
- Treatment of nonalcoholic fatty liver: present and emerging therapies.
- Primary Biliary cirrhosis and primary sclerosing cholangitis.
- Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue.
- Primary sclerosing cholangitis: emerging new promising therapies.
- Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring System.
- Magnetic resonance cholangiography in patients with Biliary disease: its role in primary sclerosing cholangitis.
- Silymarin in the treatment of patients with primary Biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
- Cetirizine-induce cholestasis.
- Oral budesonide in the treatment of primary sclerosing cholangitis.
- Medical treatment for primary sclerosing cholangitis: risk versus benefit.
- The timing of liver transplantation in primary Biliary cirrhosis.
- Serum autoantibodies in patients with primary sclerosing cholangitis.
- Oral budesonide in the treatment of patients with primary Biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
- Independent predictors of liver fibrosis in patients with nonalcoholic steatoHepatitis.
- Time course of histological progression in primary sclerosing cholangitis.
- Methotrexate in the treatment of primary Biliary cirrhosis: the hype and the hope.
- Comparison of three doses of ursodeoxycholic acid in the treatment of primary Biliary cirrhosis: a randomized trial.
- Utilization of the Mayo risk score in patients with primary Biliary cirrhosis receiving ursodeoxycholic acid.
- Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.
- Long-term ursodeoxycholic acid delays histological progression in primary Biliary cirrhosis.
- Bone Disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.
- The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis.
- [Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months].
- Paroxysmal nocturnal hemoglobinuria presenting as acute renal failure.
- [Hodgkin''s Disease. Our 9-year experience with the 1980 protocol].
- Management of primary Biliary cirrhosis and autoimmune cholangitis.
- Recent concepts in non-alcoholic fatty liver Disease.
- GI epidemiology: nonalcoholic fatty liver Disease.
- The natural history of non-alcoholic fatty liver Disease in children: a follow-up study for up to 20 years.
- Treatment of non-alcoholic fatty liver Disease.
- Noninvasive assessment of fibrosis and steatosis in NASH and ASH.
- Liver Transplantation for the Treatment of Liver Metastases From Neuroendocrine Tumors: An Analysis of the UNOS Database.
- Clinical trials: Trial design in NASH--realities and challenges.
- The natural history of nonalcoholic fatty liver disease with advanced fibrosis or Cirrhosis: an international collaborative study.
- Nonalcoholic fatty liver Disease: what are the odds your patient will get a transplant?
- Diagnosing steatoHepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.
- Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver Disease.
- PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
- A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatoHepatitis.
- Bone Disease in patients with primary sclerosing cholangitis.
- Varices in early histological stage primary Biliary cirrhosis.
- Nonalcoholic fatty liver Disease increases risk of death among patients with diabetes: a community-based cohort study.
- Long-term mortality in nonalcoholic fatty liver Disease: is liver histology of any prognostic significance?
- Betaine for nonalcoholic fatty liver Disease: results of a randomized placebo-controlled trial.
- Nonalcoholic steatoHepatitis in children: a multicenter clinicopathological study.
- The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary Hemochromatosis.
- Nonalcoholic fatty liver Disease and liver transplantation.
- The bulge, booze, and the liver.
- Alendronate improves bone mineral density in primary Biliary cirrhosis: a randomized placebo-controlled trial.
- Effect of changes on body weight and lifestyle in nonalcoholic fatty liver Disease.
- The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.
- Moexipril for treatment of primary Biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
- Cholangiocarcinoma in pregnancy: a case report.
- Suspected nonalcoholic fatty liver Disease and mortality risk in a population-based cohort study.
- Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver Disease: a randomized, controlled trial.
- The natural history of Small-duct primary sclerosing cholangitis.
- Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver Disease.
- Impact of inflammatory bowel Disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
- Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study.
- Non-alcoholic fatty liver Disease.
- [Auto-antibodies in liver Disease].
- Hepatitis C and steatosis.
- Obesity and nonalcoholic fatty liver Disease.
- Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver Disease.
- Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia.
- [Cholestatic syndromes].
- Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis.
- The NAFLD fibrosis score: a noninvasive System that identifies liver fibrosis in patients with NAFLD.
- Overlap of autoimmune hepatitis and primary Biliary cirrhosis: long-term outcomes.
- Open-label pilot study of folic acid in patients with nonalcoholic steatoHepatitis.
- Clinical predictors for hepatocellular carcinoma in patients with primary Biliary cirrhosis.
- Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatoHepatitis.
- Abnormal hepatic biochemistries in patients with inflammatory bowel Disease.
- Association of primary Biliary cirrhosis and rheumatoid arthritis.
- Utility of a new model to diagnose an alcohol basis for steatoHepatitis.
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Ind Direct Access KY
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- GEHA
- Choice Care PPO
- Preferred PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (AGAF)
- Fellow (FACG)
Drug Facts
| NPI NUMBER | 1124169602 | |
| NPPES Provider LastName | ANGULO | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 405360298 | |
| NPPES Provider State | KY | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 258.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124169602 |
| Last Name Of The Provider | ANGULO |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Matthew D. Ashmun, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deborah R. Flomenhoft, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen P. Schindler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Adalberto R. Castellanos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott A. Merkley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wesam M. Frandah, MD |
|
|
Dr. Warren N. Frank, MD |
|
|
Dr. Willem J. Devilliers, MD |
|
|
Dr. Patrick Mosler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven I. Shedlofsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen C. Schindler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Shashank Garg, MB BS |